Positron Corporation (OTC: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, announced that Manhattan Isotope Technology, with the support of Positron, has executed a Memorandum of Understanding with the ARRONAX Cyclotron Facility in Nantes, France. Manhattan Isotope and ARRONAX will collaborate on production of strontium-82 and other medical radionuclides.
As previously announced Positron has entered into a binding Letter of Intent with Manhattan Isotope Technology LLC that will make MIT a wholly owned subsidiary of Positron pending upon final transaction closing.
ARRONAX stands for Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic. ARRONAX GIP, a French GIP (Groupement d’Interet Public) operates a 70 MeV, cyclotron and associated support facilities. Arronax is located in Nantes on the campus of the university hospital and the ICO cancer center.
The company closed at $0.0158 after increasing 12.86% on Thursday.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.